Seeking Alpha

JPMorgan weighs in on the Gilead Sciences (GILD -1.1%)-Pharmasset (VRUS -2.3%) merger after...

JPMorgan weighs in on the Gilead Sciences (GILD -1.1%)-Pharmasset (VRUS -2.3%) merger after Pharmasset amended its phase 2b quantum trails this morning, rocking the boat of hepatitis C-related companies. "This announcement does not trigger a 'key product event' of the merger agreement. As such, we anticipate the deal will close on schedule."
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs